| Author | Reis, Betina Soares dos | |
| Author | Staub, Felipe Cintra | |
| Author | Koishi, Andrea Cristine | |
| Author | Zanluca, Camila | |
| Author | Santos, Claudia Nunes Duarte dos | |
| Author | Skare, Thelma L. | |
| Author | Kahlow, Bárbara Stadler | |
| Access date | 2021-11-25T14:46:13Z | |
| Available date | 2021-11-25T14:46:13Z | |
| Document date | 2021 | |
| Citation | REIS, Betina Soares dos et al. Seroconversion of rheumatoid arthritis patients after yellow fever vaccination. Clinical Rheumatology, p. 1-4, Oct. 2021. | pt_BR |
| ISSN | 1434-9949 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/50061 | |
| Language | por | pt_BR |
| Publisher | Springer Verlag | pt_BR |
| Rights | restricted access | pt_BR |
| Title | Seroconversion of rheumatoid arthritis patients after yellow fever vaccination | pt_BR |
| Type | Article | |
| DOI | 10.1007/s10067-021-05962-7 | |
| Abstract | Vaccination is a current strategy used to prevent infections in patients with immune-mediated rheumatic diseases. However, the use of live-attenuated vaccines prepared from living microorganisms in these patients should be avoided due to the risk of acquiring infections. The present study aimed to investigate the efect of the yellow fever (YF) vaccine (a live-attenuated vaccine) in 12 patients with rheumatoid arthritis (RA). The sample comprised 12 patients (9 females and 3 males; mean age 52.2±6.5 years) with RA, who inadvertently received fractionated 17D yellow fever vaccination during an outbreak of this disease. In this cohort, 10 were administered lefunomide; 7 were administered methotrexate; 6 were administered prednisone (median dose of 5.0 mg/day); 6 took biologic drugs; and 1 took tofacitinib. All but one patient (used rituximab, prednisone,
and methotrexate) seroconverted. None of them developed clinical signs of infection after the procedure. The fractionated dose of the YF vaccine is efective and safe in the observed sample. | pt_BR |
| Affilliation | Pontifícia Universidade Católica do Paraná. Curitiba, PR, Brasil. | pt_BR |
| Affilliation | Pontifícia Universidade Católica do Paraná. Curitiba, PR, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Virologia Molecular. Curitiba, PR, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Virologia Molecular. Curitiba, PR, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Virologia Molecular. Curitiba, PR, Brasil. | pt_BR |
| Affilliation | Hospital Evangélico Mackenzie. Unidade de Reumatologia. Curitiba, PR, Brasil. | pt_BR |
| Affilliation | Pontifícia Universidade Católica do Paraná. Curitiba, PR, Brasil / Hospital Evangélico Mackenzie. Unidade de Reumatologia. Curitiba, PR, Brasil. | pt_BR |
| Subject | Live-attenuated vaccine | pt_BR |
| Subject | Neutralizing Antibodies | pt_BR |
| Subject | Arthritis Rheumatoid | pt_BR |
| Subject | Yellow Fever | pt_BR |
| Subject in Spanish | Vacunas Atenuadas | pt_BR |
| Subject in Spanish | Anticuerpos Neutralizantes | pt_BR |
| Subject in Spanish | Artritis Reumatoide | pt_BR |
| Subject in Spanish | Fiebre Amarilla | pt_BR |
| Subject in French | Vaccins atténués | pt_BR |
| Subject in French | Anticorps neutralisants | pt_BR |
| Subject in French | Polyarthrite rhumatoïde | pt_BR |
| Subject in French | Fièvre jaune | pt_BR |
| DeCS | Vacinas Atenuadas | pt_BR |
| DeCS | Anticorpos Neutralizantes | pt_BR |
| DeCS | Artrite Reumatoide | pt_BR |
| DeCS | Febre Amarela | pt_BR |
| Embargo date | 2030-12-31 | |
| Embargo date | 2030-12-31 | |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
